Obstructive sleep apnea (OSA) and insomnia are often thought of as opposing clinical conditions, specifically in regard to alertness and sleepiness. Hyperarousal processes such as increased whole body and brain metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and elevated heart rate and sympathetic nervous system activation may play a key role in the pathophysiology of insomnia, thus causing an elevated level of alertness during both the night and daytime.\(^1,2\)

On the other hand, frequent arousals and fragmented sleep associated with OSA often lead to excessive daytime sleepiness, although daytime sleepiness is not universally present in all patients with OSA.\(^3,5\) Increasing evidence from studies suggests that insomnia and OSA frequently coexist.\(^6-12\)

In this review, we first provide background information on OSA and insomnia separately, including definitions, symptoms, and health risks. Second, we review studies examining the cooccurrence of insomnia in patients with OSA and of OSA in patients with insomnia. Third, we explore the evidence for the effect of OSA therapy on insomnia symptoms and the effect of insomnia treatments on breathing and sleep in patients with OSA and discuss the possible impact of insomnia on continuous positive airway pressure (CPAP) therapy. Finally, we discuss challenges in the evaluation and treatment of comorbid insomnia and OSA and identify future research needs.
or SDB; (b) the prevalence of diagnosed OSA or SDB in participants who were identified as having insomnia via polysomnography, interview, or questionnaires; (c) the effect of OSA or SDB treatments in participants identified as having insomnia and diagnosed OSA or SDB; and (d) hypnotic use in participants with diagnosed OSA or SDB. The first author (FSL) searched the database and reviewed identified articles to determine if each article met inclusion criteria. The search yielded 337 potential article titles for review that addressed comorbid insomnia and OSA or SDB, of which 120 were excluded for being review articles and 210 were excluded for not meeting inclusion criterion a or b. Thus, 7 articles were included in this review, which assessed the prevalence of comorbid insomnia and diagnosed OSA or SDB or complaints included sleep maintenance insomnia, sleep-onset insomnia, or early morning awakenings; 4 insomnia complaints included SOL > 30 minutes, wake up a lot, or difficulty returning to sleep once awakened.

Table 1—Prevalence of insomnia symptoms in patients with OSA.

<table>
<thead>
<tr>
<th>Source, year</th>
<th>Population</th>
<th>Age</th>
<th>Sex</th>
<th>Prevalence of insomnia symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith et al., 2006</td>
<td>102 patients diagnosed with OSA at sleep disorders center</td>
<td>53.91 ± 13.67, 18-87</td>
<td>69.5</td>
<td>39% of patients with OSA met criteria for insomnia</td>
</tr>
<tr>
<td>Chung et al., 2005</td>
<td>157 patients diagnosed with OSA by PSG</td>
<td>44.5 ± 9.6</td>
<td>93</td>
<td>42% reported at least 1 insomnia symptom</td>
</tr>
<tr>
<td>Krell et al., 2005</td>
<td>228 patients diagnosed with SDB by PSG</td>
<td>47, 20-85</td>
<td>60.4</td>
<td>54.9% reported 1 of 3 insomnia complaints</td>
</tr>
<tr>
<td>Krakow et al., 2001</td>
<td>231 patients diagnosed with SDB at sleep disorders center</td>
<td>51, 19-79</td>
<td>68.8</td>
<td>50% reported 2 of 3 insomnia complaints</td>
</tr>
</tbody>
</table>

OSA refers to obstructive sleep apnea; SDB, sleep disordered breathing; PSG, polysomnography.

OSA or SDB are associated with increased prevalence and severity of insomnia symptoms. Insomnia is defined by subtype based on frequency, duration, and etiology. The following qualitative insomnia diagnostic criteria have been suggested: sleep-onset latency or wake after sleep onset > 30 min from polysomnography (PSG), and at least 1 daytime consequence; insomnia symptoms or complaints included sleep maintenance insomnia, sleep-onset insomnia, or early morning awakenings; insomnia complaints included SOL > 30 minutes, wake up a lot, or difficulty returning to sleep once awakened.

OSA and Insomnia as Separate Conditions

**Obstructive Sleep Apnea**

OSA is defined by repetitive apneas and hypopneas caused by upper airway collapse during sleep, despite persistent ventilatory efforts. OSA severity is most often characterized by the number of apneas and hypopneas per hour of sleep, with an apnea-hypopnea index (AHI) of between 5 and 14 considered as mild, 15 to 29 as moderate, and 30 or greater as severe. The termination of apneas and hypopneas is associated with a transient arousal from sleep. Sleep disruption due to frequent arousals may lead to excessive daytime sleepiness or fatigue. Loud snoring or witnessed breathing interruptions are often reported by the bedpartner and the patient. Patient reports of awakening with a sensation of gasping or choking are characteristic of OSA.

**Insomnia**

Insomnia can be defined as a symptom comprising sleep-specific complaints—such as difficulty falling asleep, difficulty staying asleep, early awakenings, or unrefreshing or nonrestorative sleep—or as a disorder denoting sleep and waking symptoms. Depending on the conceptualization of insomnia, prevalence rates of insomnia can vary widely, from 6% to 48%. Typically, insomnia is defined by subtype based on frequency, duration, and etiology. The following qualitative insomnia diagnostic criteria have been suggested: sleep-onset latency or wake after sleep onset greater than 30 minutes, occurring at least 3 times per week, and with duration of at least 6 months. Using only sleep-specific insomnia symptoms for sample characterization may be a suboptimal approach to defining clinically significant insomnia. The inclusion of daytime symptoms along with sleep complaints has been recommended as a more acceptable definition of insomnia in research practice, given that daytime symptoms often prompt treatment seeking.

**Health Risks**

In addition to several symptoms, insomnia and OSA also share a number of negative consequences, including decreased health-related quality of life, psychological symptoms, and increased work-related impairments such as absenteeism and lost work productivity (Figure 1). Decreased vigilance or falling asleep at the wheel may impair driving performance, thus increasing the risk of motor vehicle crashes in patients with either OSA and insomnia. Short sleep duration associated with insomnia may increase cardiovascular risk and, in particular, the risk of developing hypertension. Additionally, OSA is a risk factor for cardiovascular disease (e.g., hypertension, coronary artery disease, congestive heart failure, and stroke) and is common in those with existing cardiovascular disease. Insomnia is a typical symptom of psychiatric disorders and may be an independent risk factor for the development of such disorders. Insomnia and OSA pose considerable safety and health problems for patients. The impact on health is likely to be increased when the conditions coexist.

**Prevalence of Comorbid Insomnia and OSA**

The association between insomnia and OSA was described by Guilleminault and colleagues in 1973. Subsequently, limited attention has been given to the presence of comorbid insomnia in OSA. A high prevalence (39% to 55%) of insomnia...
Symptoms of obstructive sleep apnea and insomnia were derived from the International Classification of Sleep Disorders-2nd edition criteria for obstructive sleep apnea syndrome and general insomnia disorder, except for hyperarousal, anxiety about sleep, and learned associations, which were adopted from criteria for psychophysiological insomnia.

![Figure 1](image-url) The interrelationship between symptoms and clinical factors associated with obstructive sleep apnea and insomnia.
and daytime consequences of sleep disturbances. Although the prevalence of insomnia in OSA appears to be high, a clearer understanding of the magnitude of this comorbidity will require more standardized methods for characterizing clinically significant insomnia in OSA.

**COMORBID OSA IN INSOMNIA**

OSA in patients presenting with insomnia complaints has been examined in several studies (Table 2). Lichstein and colleagues found that 29% of older adults with insomnia recruited for a research study (n = 80) had polysomnography-diagnosed OSA (AHI > 15), even after those with a high index of suspicion for OSA were excluded by screening clinical interview. In a case-control study (N = 200), approximately 30% of community-dwelling elderly adults with insomnia had diagnosed SDB (AHI ≥ 15), although this percentage was lower in those without insomnia (38%). Among 394 postmenopausal women with chronic insomnia complaints without major psychiatric or medical disorders, 67% (n = 264) had an AHI of at least 5, based on either home monitoring or polysomnography.

**Clinical Factors Associated With Comorbid Insomnia and OSA**

Few of the identified studies considered the relationship between population characteristics and comorbid OSA and insomnia. In those that did, 4 studies found no difference in age and 2 studies found no differences in sex between those with OSA and insomnia and those with only OSA or insomnia. In 1 study, more women than men had OSA and insomnia (51.4% vs 48.6% with OSA or insomnia only). In contrast, as compared with those with insomnia only, more men than women had comorbid OSA and insomnia. As compared with Hispanics, non-Hispanic whites comprised a significantly greater proportion of patients with SDB and insomnia.

One study reported a significant difference in the rates of psychiatric disorders between patients with OSA and insomnia and those with only OSA (47.8% vs 28.7%, respectively). Insomnia complaints in those with OSA were associated with chronic pain and symptoms of restless legs. Krakow and colleagues found that patients with SDB and insomnia reported more cognitive-emotional complaints (i.e., attention or concentration, memory, depressed feelings, anxious feelings, irritability, hostility, frustration, and claustrophobia), mental symptoms (i.e., racing thoughts and rumination, anxiety and fear), physical symptoms (i.e., trouble breathing, restless legs, indigestion, and pain), and psychiatric disorders than did patients with only SDB. Similarly, in a sample of patients referred for investigation of OSA, those with diagnosed OSA and whose symptoms also met the criteria for insomnia reported significantly more symptoms of depression, anxiety, and stress than did patients diagnosed with only OSA. Patients with OSA and insomnia also endorsed more dysfunctional beliefs about sleep, in particular, concerns about the long-term consequences of poor sleep on behavior and higher levels of need for control over sleep.

In a community sample of older adults, those with insomnia and OSA reported more snoring and witnessed apneas and were more likely to have a body mass index of 30 or greater and a neck size 15 inches or larger, as compared with older adults with only insomnia. Comparatively, no differences in body mass index or snoring were found between a research sample of older adults with insomnia and OSA or with insomnia but no OSA. The insomnia plus OSA group had lower scores on the Geriatric Depression Scale (mean = 2.7, SD = 2.3) than did the insomnia-only group (mean = 4.9, SD = 4.5), although the mean scores were both within the normal range. No differences in excessive daytime sleepiness, sleep efficiency, or frequent awakenings were found between older adults with insomnia and OSA and those with insomnia only in both the community and research samples. Among postmenopausal women with insomnia, women with an AHI of 5 or greater and those with an AHI of less than 5 had similar scores on the Epworth Sleepiness Scale and similar objective total sleep time and sleep latencies.

**Treatment of Comorbid Insomnia and OSA**

Limited information is available regarding the concurrent treatment of these comorbid sleep disorders. Sequential OSA therapy and cognitive behavior therapy (CBT) in patients with comorbid insomnia and OSA has been examined in 2 studies. Studies examining the use of hypnotic agents in patients with OSA have primarily focused on measures of breathing during sleep and acceptance and adherence to CPAP and have not examined the effect of these drugs on sleep in patients with OSA and insomnia.

**Treatment of OSA in Patients With Chronic Insomnia**

Adults with sleep-maintenance insomnia and OSA symptoms randomly assigned to receive nasal-dilator-strip therapy reported greater improvements in insomnia severity and sleep

---

**Table 2**—Prevalence of obstructive sleep apnea in patients with insomnia.

<table>
<thead>
<tr>
<th>Source, year</th>
<th>Population</th>
<th>Age</th>
<th>Sex</th>
<th>Prevalence of insomnia symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gooneratne et al., 2006</td>
<td>200 community-dwelling older adults—100 with insomnia symptoms and 100 without insomnia symptoms</td>
<td>55-70</td>
<td>65.8</td>
<td>29.3% of older adults with insomnia had an AHI ≥ 15.</td>
</tr>
<tr>
<td>Guilleminault et al., 2005</td>
<td>394 postmenopausal women with chronic insomnia complaints</td>
<td>69.4 ± 7.2, 59-92</td>
<td>60</td>
<td>29% had an AHI &gt; 15 and 43% had an AHI &gt; 5 during PSG.</td>
</tr>
<tr>
<td>Lichstein et al., 2005</td>
<td>80 older adults ineligible for insomnia research due to suspected OSA, PLM, or RLS.</td>
<td>71.9 ± 5.0</td>
<td>100</td>
<td>67% had an AHI &gt; 5 during portable monitoring or PSG.</td>
</tr>
</tbody>
</table>

AH1 refers to apnea-hypopnea index; PSG, polysomnography; OSA, obstructive sleep apnea; PLM, periodic limb movements; RLS, restless legs syndrome. Data are presented as mean ± SD, range; Data are presented as the percentage of women.
quality than did those who received only education. Krakow and colleagues examined the effect of SDB treatment (CPAP, oral appliances, or bilateral turbinectomy) on sleep measures in patients with chronic insomnia and SDB who completed a CBT program. Both treatment phases (baseline to 3 months after completing CBT program and CBT follow-up to after maintaining 3 months’ use of SDB therapy) resulted in improvements in insomnia severity and sleep-related daytime impairments. However, CBT alone had only a small effect on daytime impairments. After CBT, only 8 out of 17 patients attained a nonclinical level of insomnia, compared with 15 patients who received both CBT therapy and treatment for SDB. Combination therapy that included both CBT and OSA treatment resulted in greater improvements in insomnia complaints than did CBT alone. In a prospective crossover study, 30 patients with complaints of insomnia and mild OSA, matched for age and sex, received either CBT or surgical treatment of OSA as primary treatment, followed by the alternative treatment if agreeable. Treatment of OSA alone was successful in eliminating complaints of insomnia in 5 out of 15 participants, whereas none of the participants receiving CBT alone felt that the insomnia complaints had resolved. More specifically, surgical intervention for OSA demonstrated greater initial improvements in subjective and objective sleep quality and respiratory measures than did CBT. However, CBT following surgical intervention provided additional benefits of further increasing total sleep time and decreasing sleep-onset latency by addressing the behavior component of conditioning and other residual sleep problems. Results of this study suggest that treating both insomnia and OSA together is the best approach for addressing comorbid insomnia and OSA. Treatment of the breathing problem alone was not successful in eliminating insomnia complaints in all patients, which argues for the presence of an insomnia-OSA phenotype.

Treatment of Insomnia in Patients With OSA

The use of benzodiazepines in patients with sleep apnea has been limited because the use of these drugs is associated with reduced upper airway muscle tone and decreased ventilatory response to hypoxia, thus potentially increasing the AHI and prolonging events. In a study comparing 30 mg of flurazepam with placebo, the flurazepam group had an increased number of apnea episodes (9.95 vs 5.35) and a longer duration of apneas (3.44 minutes vs 1.72 minutes). Increases in arousal threshold resulting in modest prolongation of event duration and increased desaturation have been documented with administration of triazolam in patients with severe OSA. However, the use of benzodiazepines in other studies has resulted in no significant changes in respiration. In 1 study, a dose of 15 to 30 mg of temazepam did not increase the respiratory disturbance index in elderly patients with mild sleep apnea and insomnia (8.8 ± 5.3), as compared with the nondrug group that received placebo or behavior therapy (9.2 ± 2.8). In summary, the effects of benzodiazepines on OSA are modest at best. Studies have investigated the use of GABAergic nonbenzodiazepine agents ( zaleplon, zolpidem, eszopiclone) in patients with OSA. Nonbenzodiazepine agents have hypnotic and sedative effects similar to those of benzodiazepines, but some (especially those selective for GABA receptors containing \( \alpha_1 \) subunits) may have fewer muscle-relaxant effects, thus offering a more favorable treatment approach to insomnia in OSA. A pilot study evaluating the use of eszopiclone, a selective GABAergic nonbenzodiazepine agent, in patients with mild to moderate OSA found no significant differences in mean AHI scores, total arousals, respiratory arousals, duration of apnea and hypopnea episodes, or oxygen saturation between patients treated with placebo and those treated with eszopiclone. Patients treated with eszopiclone experienced improved sleep duration and sleep efficacy and reduced wake time during sleep and wake time after sleep onset. Administration of 3 mg of eszopiclone prior to diagnostic polysomnography or CPAP titration significantly reduced sleep latency, improved sleep efficiency, reduced wake time after sleep onset, prolonged sleep time, and did not worsen the severity of SDB or impair airway stability. In a study of 16 patients with severe OSA who were treated with an effective level of CPAP, administration of 10 mg of zolpidem did not increase the AHI or oxygen desaturation index. Sleep architecture did not differ between zolpidem and placebo nights except for a reduction in sleep latency and the mean arousal index on zolpidem nights. This study suggests that zolpidem does not impede CPAP efficacy in patients with severe OSA. A dose of 20 mg of zolpidem, which is above the recommended hypnotic dose, did increase the apnea index and oxygen desaturation, suggesting that the usual therapeutic doses of zolpidem should not be exceeded when treating patients with OSA.

The efficacy of selective nonbenzodiazepine agents for improving adherence to CPAP therapy in patients with OSA who complain of insomnia symptoms has not been documented. One study comparing the use of 10 mg of zolpidem, placebo, and standard therapy (no hypnotic or placebo pill) in men with OSA did not show greater CPAP usage, compared with placebo and standard therapy. In contrast, administration of 3 mg of eszopiclone for the first 14 nights of CPAP use in adults newly diagnosed with OSA has been shown to improve CPAP adherence and lead to lower discontinuation rates at 6-month follow-up, compared with placebo. The use of hypnotics for those initiating CPAP treatment appears to be safe and may be beneficial in facilitating better CPAP tolerance and improving adherence, especially for patients who report difficulty initiating or maintaining sleep.

INSOMNIA AND CPAP ADHERENCE

CPAP is the conventional therapy for most patients with OSA, and its use has been shown to be associated with improvements in sleep quality, cognitive function, and quality of life and reductions in daytime sleepiness and respiratory disturbances. Adherence to CPAP is often poor, with 29% to 83% of patients reporting using CPAP for less than 4 hours per night. Research investigating the association between comorbid insomnia and CPAP use in patients with OSA has not been conducted. Insomnia may have direct or indirect effects on CPAP adherence. Patients with OSA and insomnia may have more difficulty adhering to CPAP because of increased awareness of the mask due to frequent awakenings and an inability to initiate or return to sleep with the mask in place. Psychiatric disorders, such as anxiety and depression, often coexist with insomnia and may also play a role in CPAP adherence. For example, anxious patients may be more likely to have claustrophobia, which is
Evaluation of Comorbid Insomnia and OSA

The evaluation of comorbid insomnia in OSA can be challenging, given that symptoms of these 2 conditions overlap substantially and that methods for evaluation are similar. Sleep associated with poor CPAP adherence. In 1 study, almost one third (30%) of participants with OSA and comorbid insomnia who showed resistance to using CPAP therapy reported having a history of claustrophobia. Early CPAP use is predictive of later use; therefore, establishing an optimal pattern of adherence at the initiation of CPAP therapy is crucial for patients with OSA and insomnia who may have particular difficulty accepting and adhering to CPAP. In a recent pilot study (PAP-NAP), a combination of psychological and physiologic treatments were conducted prior to a full-night of positive airway pressure (PAP) therapy titration in a sample of patients with SDB and insomnia who had psychiatric symptoms or disorders and who manifested a resistance to PAP therapy. The treatments included pretest instructions on how to prepare for the study, desensitization to the masks and pressurized airflow through emotional processing and mental imagery, PAP therapy hookup in the laboratory if needed, and an opportunity for patients to use the PAP therapy for more than 1 hour and have the potential to fall asleep with the mask in place in the laboratory. The 39 patients completing the PAP-NAP study, as compared with historical controls, were more likely to complete the overnight titrations (90% vs 63%), fill the PAP therapy prescriptions for home use (85% vs 35%), and maintain regular use of PAP therapy (67% vs 23%). Acclimating patients with OSA and comorbid insomnia to CPAP therapy may improve the likelihood of patients regularly using CPAP. A key element to facilitating adherence to CPAP therapy may also be to address comorbid insomnia symptoms using a hypnotic agent, CBT, or a combination thereof prior to the initiation of CPAP.

CHALLENGES AND FUTURE RESEARCH

Comorbid Insomnia and Obstructive Sleep Apnea

Figure 2—The relationship between self-reported sleepiness and sleep apnea.

Depicted are data from the Epworth Sleepiness Scale, which is administered as part of the standard intake at the University of Pittsburgh Medical Center Sleep Medicine Center. Data were collected from 4653 consecutive patients over 5 years.

The degree to which the comorbid insomnia-OSA phenotype coexist with disorder nosologies also present limitations for the evaluation of comorbid insomnia and OSA. General insomnia in both the International Classification of Sleep Disorders, 2nd edition (ICSD-2) and the Research Diagnostic Criteria (RDC) for Insomnia is defined by the following general criteria: (A) 1 or more sleep-related complaints: difficulty initiating sleep, difficulty maintaining sleep, waking up to early, or chronically nonrestorative or poor quality sleep; (B) above sleep difficulty occurs despite adequate opportunity and circumstances for sleep; and (C) at least 1 daytime impairment related to the nighttime sleep difficulty, such as daytime sleepiness or fatigue. The ICSD-2 criteria for the diagnosis of OSA overlap with the above ICSD-2 criteria for general insomnia, such that complaints of unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, and insomnia are included as criteria. The RDC for Insomnia proposes the following criteria for diagnosing insomnia related to sleep apnea: (A) individual meets criteria for insomnia disorder; (B) polysomnography shows more than 5 respiratory events per hour of sleep that meet current definitional criteria for apneas, hypopneas, or respiratory effort-related arousals; and (C) medical disorders, mental disorders, and any coexisting sleep disorder cannot completely account for the insomnia. Similar to the ICSD-2 criteria for OSA, the RDC criteria for insomnia related to sleep apnea require clinicians to decide whether sleep complaint(s) and daytime impairment(s) are due to frequent arousals and sleep fragmentation associated with OSA or if they are representative of insomnia. For this reason, the 2005 National Institutes of Health State-of-the-Science conference on insomnia recommended that “comorbid insomnia” may be a more appropriate term than “secondary insomnia” or “insomnia due to.”

Recently published clinical guidelines for the evaluation of chronic insomnia suggest that 3 major groupings of insomnia can be considered when diagnosing insomnia and insomnia-related-disorders: insomnia associated with other sleep disorders; insomnia related to medical or psychiatric disorders or drug or substance use; and primary insomnias, including idiopathic, paradoxical, and psychophysiological insomnia. Furthermore, comorbid insomnias and multiple insomnia diagnoses may coexist. In patients with diagnosed OSA, identifying other medical or psychiatric disorders that may cause sleep difficulties will be important for identifying additional etiologies of insomnia complaints. Assessment of learned negative sleep behaviors—including spending more time in bed to “catch up” on sleep; eating, exercising, or smoking before bed; and watching television, using a computer, or “clock watching” when in bed or in the bedroom—and cognitive distortions is essential for evaluating patients for primary insomnia disorders.

Polysomnography is not routinely used in the evaluation of chronic insomnia. However, in cases in which pharmacotherapy and behavior therapy are ineffective in ameliorating insomnia symptoms, patients should be referred for polysomnography to be evaluated for OSA. Patients with cooccurring insomnia and OSA are a challenging patient population for evaluation and treatment. It is likely that comorbid insomnia in OSA is a discreet phenotype similar to the sleepy and nonsleepy phenotype previously reported in OSA (Figure 2). The degree to which the comorbid insomnia-OSA phenotype coexist with
the sleepy-nonsleepy phenotype is unknown. Multidisciplinary collaboration among sleep specialists and psychiatrists and psychologists will likely yield the most successful outcomes.

Treatment of Comorbid Insomnia and OSA

The optimal strategy for adequately treating coexisting insomnia and OSA remains unclear given the limited research examining this topic. The 2 studies that examined sequential OSA therapy and CBT suggest that concurrent treatment for both sleep disorders may be the best treatment approach.35,36 However, the treatment options for insomnia and OSA present many challenges. Treatment of OSA in patients with insomnia may be difficult because CPAP therapy might increase awakenings, thus perpetuating insomnia symptoms. Additionally, patients with insomnia may be experiencing hyperarousal or anxiety, which may impede the initiation and continuation of CPAP therapy.

As with treatments for OSA, treatments for insomnia also present challenges for patients and care providers. The efficacy of the long-term use of hypnotics has not been evaluated in patients with OSA. Side effects of benzodiazepines—including habituation, dependency, rebound effects, and withdrawal—may pose potential problems. Benzodiazepines prolong the duration of SDB events.34,40 Nonbenzodiazepine agents appear to have little or no effect on respiration and have fewer side effects and drug interactions than do benzodiazepines. Preliminary investigations into the efficacy of nonbenzodiazepine agents in patients with OSA suggest that these hypnotics may improve patient tolerance of CPAP and increase total sleep time and sleep continuity, thus helping to facilitate better more-effective CPAP titration.42,44-45

CBT has been shown in numerous studies to be effective in improving insomnia symptoms in those with primary and comorbid insomnia.63,64 Nonetheless, CBT is an intensive intervention requiring a high degree of motivation on the patient’s behalf. Future treatment studies in comorbid insomnia and OSA are needed. Sequenced studies with CPAP therapy, CBT, and hypnotics will provide greater insight into the optimal treatment strategies for patients with comorbid insomnia and OSA. Additionally, clinical trials evaluating the effectiveness of the chronic use of nonbenzodiazepine agents on insomnia symptoms in patients with insomnia and OSA are warranted.

Future Research

Insomnia and OSA are 2 of the most prevalent sleep disorders; thus, we would expect some degree of coexistence within patients. However, the high prevalence of comorbid insomnia and OSA found in available studies6-12 suggests that these disorders exacerbate one another and, when unaddressed, represent a barrier to effective overall treatment of the combined sleep disturbance. One could assume that daytime sleepiness often reported by patients with OSA may decrease the likelihood of insomnia symptoms or that the hyperaroused state of insomnia could reduce upper airway collapsibility. However, OSA could exacerbate insomnia symptoms as a result of sleep fragmentation and poor sleep quality.7 Patients with OSA have reported fear of dying during sleep, which could potentially result in a fear of sleep that could present as psychophysiology insomnia.65 Alternatively, sleep fragmentation that is commonly associated with insomnia may worsen OSA by increasing lighter stages of non-rapid eye movement sleep or by negatively affecting upper-airway muscle tone.66 Insomnia may also be a potential symptom of OSA; in particular, sleep maintenance insomnia could be the product of OSA-provoked arousals.6 In a recent review, Beneto67 hypothesized that activation of the hypothalamic-pituitary-adrenal axis and its impact on the metabolic syndrome may be a potential link between insomnia and OSA. Sleep fragmentation resulting from OSA and, potentially, insomnia has been suggested to increase sympathetic activity and activity of the hypothalamic-pituitary-adrenal axis. Understanding the nature of the relationship between insomnia and OSA may help to inform treatment strategies for patients with both disorders.

The clinical presentation and treatment of these coexisting sleep disorders requires additional research. Thus far, studies examining comorbid insomnia and OSA have identified patients with 1 of the conditions and then examined the prevalence of the other condition in the sample, consequently making it difficult to truly determine the prevalence of OSA in insomnia or vice versa. Variability in the definitions of insomnia and OSA in available studies also prohibits us from determining the true overlap of these conditions. For example, frequent arousals may be classified as insomnia when they could be due to OSA, and, as such, many patients with OSA could be misclassified as having sleep-maintenance insomnia. To obtain a more accurate prevalence of comorbid insomnia and OSA, it may be helpful to have a broad sample of patients without preclassification as having either OSA or insomnia undergo polysomnography. More precise phenotyping of clinical and polysomnographic features of comorbid insomnia and OSA using population and clinical studies is needed.

Insomnia and OSA are risk factors for cardiovascular disease.23,28 To date, investigations into the impact of comorbid insomnia and OSA on cardiovascular risk and other health outcomes have yet to be conducted. Understanding the health impact of comorbid insomnia and OSA is important for furthering our understanding of this growing patient population.

Insomnia is a symptom of psychiatric disorders and also a risk factor for the development of these disorders.32,33 Patients with OSA who also report having insomnia symptoms have a higher rate of psychiatric comorbidities than do patients with only OSA. In these studies, no differences in depression symptoms were found between patients with insomnia and OSA and those with only insomnia. Psychiatric comorbidities may contribute to the occurrence of insomnia in patients with OSA. Investigations into the potential role of psychiatric disorders as a contributing factor in the association between insomnia and OSA are needed.

The association between insomnia and CPAP adherence is an important, yet unexplored, research area. Some interesting questions about this potential relationship include whether comorbid insomnia negatively impacts CPAP adherence, whether treatment of OSA with CPAP can ameliorate insomnia symptoms, and the effect of comorbid insomnia on the efficacy of or outcomes associated with CPAP among those who are compliant. Understanding the role of insomnia in the treatment of OSA will be critical for the management of patients with comorbid insomnia and OSA.
CONCLUSIONS

Although insomnia and OSA frequently coexist, the prevalence of comorbid insomnia and OSA varies, primarily because of the variability in how insomnia and OSA are defined and characterized. It seems likely that concurrent treatment of insomnia and OSA would be the best treatment approach, but additional research is needed to determine the effectiveness of combination treatment in this patient population. Understanding the potential impact of insomnia on CPAP therapy will be important for the successful long-term disease management of OSA in patients with comorbid insomnia and OSA.

REFERENCES

35. Guilleminault C, Davis K, Huynt NH. Prospective randomized study of patients with insomnia and mild sleep disordered breathing. Sleep 2008;31:1527-33.
43. Bradshaw DA, Ruff GA, Murphy DP. An oral hypnotic medication does not improve continuous positive airway pressure compliance in men with obstructive sleep apnea. Chest 2006;130:1369-76.
FS Lyster, DJ Buysse, PJ Strollo


ACKNOWLEDGMENTS

Supported by NIH grants HL082610 and MH024652.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication October, 2009
Submitted in final revised form December, 2009
Accepted for publication December, 2009
Address correspondence to: Faith S. Lyster, University of Pittsburgh, 3500 Victoria Building, Room 366A, Pittsburgh, PA 15261; Tel: (412) 624-7910; Fax: (412) 624-1508; E-mail: luysterfs@upmc.edu

DISCLOSURE STATEMENT

This was not an industry supported study. Dr. Buysse has received research support from Sepracor; has consulted for Actelion, Arena, Cephalon, Eli Lilly, GlaxoSmithKline, Merck, Neurocrine, Neurogen, Pfizer, Respirationics, Sanofi-Aventis, Sepracor, Servier, Somnus Therapeutics, Stress Eraser, Takeda, and Transcept Pharmaceuticals; and has helped to produce CME materials and has given paid CME lectures indirectly supported by industry sponsors. Dr. Strollo has received research support from ResMed Corp. and Respirationics. Dr. Luyster has indicated no financial conflicts of interest.